$ECTE ANALYSIS – JUNE 1 2016

/ / FaisamTrader Blog, Stock Analysis

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation

and diagnostic medical devices for wearable-health consumer and diabetes outpatient

markets. It is developing continuous glucose monitoring (CGM) system, a needle-free

wireless continuous glucose monitoring system in a hospital setting in the European

Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to

develop, manufacture, distribute, and market devices for skin preparation prior to the

application of topical anesthetics or analgesics prior to a range of needle-based medical

procedures in North America, the United Kingdom, South America, Australia, New

Zealand, Switzerland, and other portions of the European Community. In addition, it has

a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market,

import, and sell CGM to medical facilities and individual consumers in South Korea; and

a license, development, and commercialization agreement with Medical Technologies

Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's

Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989

and is headquartered in Iselin, New Jersey.

 

As of June 1 2016, ECTE looks to be bullish, for a 2 to 3 week hold. A purchase at a

price between $1.60 and $1.80 is safe and could bring you returns between 10% and

15% in the next 30 days. Be sure you place a stop loss at 5% below you buy price, and

don’t be greedy, a consistent 10% to 15% per month can help dealing with losses and

sometimes help bring in more profits.

 

Also please keep in mind we are not offer trading advice, we are just sharing an idea.

For real stock trading advice you should contact a professional financial advisor.

faq-bot-banner2

You must be logged in to post a comment.